A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
NCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05923008 Brief Summary This is a phase 1/2 multicenter, open-label, first-in-human…
Read more arrow_forwardNCT 06305767 Brief Summary Researchers are looking for new ways to treat…
Read more arrow_forwardNCT 05858164 Brief Summary Researchers are looking for a better way…
Read more arrow_forwardNCT 04801095 Brief Summary This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read more arrow_forwardNCT 05332574 Brief Summary This is a Phase 1/2 study of GB263T…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 05381909 Brief Summary This study aims to understand how safe and…
Read more arrow_forwardNCT 05935098 Brief Summary This study aims to test the safety, tolerability,…
Read more arrow_forwardNCT 05346484 Brief Summary This is an open-label, dose-escalation, multi-center phase I…
Read more arrow_forward